Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Add to Home Screen/Install App' to create a shortcut app

References for Neurocysticercosis in Children

This page was last updated on April 8th, 2024

  1. de Oliveira RS, Viana DC, Colli BO, R el al. Pediatric neurocysticercosis. Child’s Nerv Syst. 34(10):1957–65, 2018
  2. Rajshekhar V. Surgical management of neurocysticercosis. Int J Surg.  8(2):100–4, 2010
  3. Ndimubanzi PC, Carabin H, Budke CM, et al. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis. 4(11), 2010
  4. Pal DK, Carpio A, Sander WAS. Neurocysticercosis and epilepsy in developing countries. J Neurol Neurosurg Psychiatry. 68(2):137–43, 2000
  5. Colli BO, Carlotti CGJ, Assirati JAJ, el al. Surgical treatment of cerebral cysticercosis: long-term results and prognostic factors. Neurosurg Focus. 2002
  6. Ortu G, Williams O. Neglected tropical diseases: Exploring long term practical approaches to achieve sustainable disease elimination and beyond. Infect Dis Poverty. 6(1):1–12, 2017
  7. Bouteille B. Epidemiology of cysticercosis and neurocysticercosis. Med Sante Trop. 24(4):367–74, 2014
  8. Gonzales I, Rivera JT, Garcia HH. Pathogenesis of Taenia solium taeniasis and cysticercosis. Parasite Immunol. 38(3):136–46, 2016
  9. Del Brutto VJ, Del Brutto OH, Ochoa E, et al. Single parenchymal brain cysticercus: relationship between age of patients and evolutive stage of parasites. Neurol Res. 34(10):967–70, 2012
  10. Assana E, Lightowlers MW, Zoli AP, et al. Veterinary Parasitology Taenia solium taeniosis / cysticercosis in Africa : Risk factors , epidemiology and prospects for control using vaccination. Vet Parasitol. 195(1–2):14–23, 2013
  11. Carpio A, Fleury A, Romo ML, et al. New diagnostic criteria for neurocysticercosis: Reliability and validity. Ann Neurol. 80(3):434–42, 2016
  12. Lobato RD, Lamas E, Portillo JM, et al. Hydrocephalus in cerebral cysticercosis. J Neurosurg. 55(5):786–93, 1981
  13. Serpa JA, Clinton White A. Neurocysticercosis in the United States. Pathog Glob Health. 106(5):256–60, 2012
  14. Del Brutto OH, García HH. Neurocysticercosis in Nonendemic Countries: Time for a Reappraisal. Neuroepidemiology. 39(2):145–6, 2012
  15. McLachlan RS. Julius Caesar’s late onset epilepsy: A case of historic proportions. Can J Neurol Sci. 37(5):557–61, 2010
  16. Bruschi F. Was Julius Caesar’s epilepsy due to neurocysticercosis? Trends Parasitol. 27(9):373–4, 2011
  17. Del Brutto OH, García HH. Taenia solium Cysticercosis – The lessons of history. Journal of the Neurological Sciences 359: 392–5, 2015
  18. Centers for Disease Control and Prevention: Recommendations of the International Task Force for Disease Eradication, 1993 ( [Accessed 23 Septembre 2020]
  19. Sotelo J, Escobedo F, Rodriguez-Carbajal J, et al. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med. 310(16):1001–7, 1984
  20. Apuzzo MLJ, Dobkin WR, Zee C-S,et al. Surgical considerations in treatment of intraventricular cysticercosis. J Neurosurg. 60(2):400–7, 2009
  21. World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation, 2012 ( [Accessed 23 Septembre 2020]
  22. World Health Organization. WHO estimates of the global burden of foodborne diseases Foodborne diseases burden epidemiology reference group 2007-2015, 2015 (  [Accessed 23 Septembre 2020]
  23. Raina SK, Razdan S, Pandita KK, et al. Active Epilepsy as Indicator of Neurocysticercosis in Rural Northwest India. Epilepsy Res Treat. 2012; 1–4, 2012
  24. World Health Organization. Taeniasis/cysticercosis, 2019 ( [Accessed 23 Septembre 2020]
  25. Zammarchi L, Strohmeyer M, Bartalesi F, et al. Epidemiology and Management of Cysticercosis and Taenia solium Taeniasis in Europe, Systematic Review 1990-2011. PLoS One. 8(7), 2013
  26. O’Neal SE, Flecker RH. Hospitalization frequency and charges for neurocysticercosis, United States, 2003–2012. Emerg Infect Dis. 21(6):969–76, 2015
  27. Openshaw JJ, Medina A, Felt SA, et al. Prevalence and risk factors for Taenia solium cysticercosis in school-aged children: A school based study in western Sichuan, People’s Republic of China. 12(5):1–23, 2018
  28. Baird RA, Wiebe S, Zunt JR, et al. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 80(15):1424–9, 2013
  29. Carabin H, Winkler AS, Dorny P. Taenia solium cysticercosis and taeniosis: Achievements from the past 10 years and the way forward. PLoS Negl Trop Dis. 11(4):e0005478, 2017
  30. White AC, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg. 98(4):945–66, 2018
  31. Alarcón F, Vanormelingen K, Moncayo J, et al. Cerebral cysticercosis as a risk factor for stroke in young and middle-aged people. Stroke. 23(11):1563–5, 1992
  32. Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol. 13(12):1202–15, 2014
  33. Delgado Hernandez RD, Boleaga Duran B, et al. Magnetic resonance imaging in neurocysticercosis. 23(3):191–8, 2014
  34. Kimura-Hayama ET, Higuera JA, Corona-Cedillo R, Chávez-Macías L, Perochena A, Quiroz-Rojas LY, et al. Neurocysticercosis: Radiologic-Pathologic Correlation. RadioGraphics. 30(6):1705–19, 2010
  35. Zymberg ST. Neurocysticercosis. World Neurosurg. 79(2):S24.e5-S24.e8, 2013
  36. Maste P, Lokanath Y, Mahantshetti S, Soumya S. Isolated intramedullary spinal cysticercosis: A case report with review of literature of a rare presentation. Asian J Neurosurg. 13(1):154, 2016
  37. Pal S, Singh N, Chowdhury N, Huda F, et al. Cysticercosis: Reiterating the role of cytodiagnosis. Diagn Cytopathol. 45(11):971–5, 2017
  38. Sander JW, Chinna D, Chaudhary A, et al. Association between epilepsy and cysticercosis and toxocariasis: A population-based case-control study in a slum in India. Epilepsia. 53(12):2203–8, 2012
  39. Singhi P, Saini AG. Pediatric Neurocysticercosis. Indian J Pediatr. 2017;1–7.
  40. de Oliveira RS, Viana DC, Colli BO, R el al. Pediatric neurocysticercosis. Child’s Nerv Syst. 34(10):1957–65, 2018
  41. Callacondo D, Garcia HH, Gonzales I, et al. High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis. Neurology. 78(18):1394–400, 2012
  42. Rangel R, Torres B, Del Bruto O, et al. Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg. 36(2):387–92, 1987
  43. Debnath B, Mazumder S, Mahbub M, et al. Cysticercal Encephalitis, A Rare Presentation of Neurocysticercosis: A Case Report. Bangladesh J Child Heal,  2015 ( [Accessed 27 September 2020]
  44. Singhi P, GAHLOT A. Pediatric neurocysticercosis: current challenges and future prospects. Pediatr Heal Med Ther. 7: 5-16, 2016
  45. Rajshekhar V, Jeyaseelan L. Seizure outcome in patients with a solitary cerebral cysticercus granuloma. Neurology. 62(12):2236–40, 2004
  46. Tsang VCW, Brand JA, Boyer AE, et al, Diseases I, Jan N. Blot Assay and Glycoprotein Antigens An Enzyme-Linked Immunoelectrotransfer for Diagnosing Human Cysticercosis ( Taenia solium ). 159(1):50–9, 2009
  47. Michelet L, Fleury A, Sciutto E, Kendjo E, Fragoso G, Paris L, et al. Human neurocysticercosis: Comparison of different diagnostic tests using cerebrospinal fluid. J Clin Microbiol. 49(1):195–200, 2011
  48. Odashima NS, Takayanagui OM, De Castro Figueiredo JF. Enzyme linked immunosorbent assay (ELISA) for the detection of IgG, IgM, IgE and IgA against cysticercus cellulosae in cerebrospinal fluid of patients with neurocysticercosis. Arq Neuropsiquiatr. 60(2 B):400–5, 2002
  49. Yamasaki H, Allan JC, Sato MO, , et al. DNA differential diagnosis of taeniasis and cysticercosis by multiplex PCR. J Clin Microbiol. 42(2):548–53, 2004
  50. Del Brutto OH, Rajshekhar V, White ACJ, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology. 57(2):177–83, 2001
  51. Poca MA, Sahuquillo J. Short-term medical management of hydrocephalus. Expert Opin Pharmacother. 6(9):1525–38, 2005
  52. Del Brutto OH, Nash TE, White ACJ, , et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 372:202–10, 2017
  53. Rajshekhar V. Rate of spontaneous resolution of a solitary cysticercus granuloma in patients with seizures. Neurology. 57(12):2315–7, 2001
  54. Kalra V, Dua T, Kumar V. Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. J Pediatr. 143(1):111–4, 2001
  55. Sundaram PM, Jayakumar N, Noronha V. Extraocular muscle cysticercosis – a clinical challenge to the ophthalmologists. Orbit. 23(4):255–62, 2004
  56. Hermans V, De Pooter F, De Groote F, et al Effect of dexamethasone on nausea, vomiting, and pain in paediatric tonsillectomy. Br J Anaesth [Internet]. 109(3):427–31, 2012
  57. García HH, Evans CAW, Nash TE, , et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 15(4):747–56, 2002
  58. Apuzzo ML, Dobkin WR, Zee CS, et al. Surgical considerations in treatment of intraventricular cysticercosis. An analysis of 45 cases. J Neurosurg. 60(2):400–7, 1984
  59. Nash TE, Mahanty S, Garcia HH. Corticosteroid use in neurocysticercosis. Expert Rev Neurother. 11(8):1175–83, 2011
  60. Baranwal AK, Singhi PD, Singhi SC, et al. Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions: prognostic factors on long-term follow-up. J Child Neurol. 16(6):443–5, 2001
  61. Centers for Disease Control and Prevention. Parasites – Cysticercosis. ( [Accessed 6 April 2020]
  62. Flisser A, Gauci CG, Zoli A, et al. Induction of protection against porcine cysticercosis by vaccination with recombinant oncosphere antigens. Infect Immun. 72(9):5292–7, 2004
  63. Gonzalez AE, Gauci CG, Barber D, et al. Vaccination of pigs to control human neurocysticercosis. Am J Trop Med Hyg. 72(6):837–9, 2005
  64. Assana E, Kyngdon CT, Gauci CG, et al. Elimination of Taenia solium transmission to pigs in a field trial of the TSOL18  vaccine in Cameroon. Int J Parasitol. 40(5):515–9, 2010
  65. Singh A, Singh AK, Singh SK, et al. Association of ICAM-1 K469E polymorphism with neurocysticercosis. J Neuroimmunol. 276(1–2):166–71, 2014
  66. Verma A, Prasad KN, Gupta RK, , et al. Toll-like receptor 4 polymorphism and its association with symptomatic neurocysticercosis. J Infect Dis. 202(8):1219–25, 2010
  67. Arora N, Tripathi S, Sao R, et al. Molecular Neuro-Pathomechanism of Neurocysticercosis: How Host Genetic Factors Influence Disease Susceptibility. Mol Neurobiol. 55(2):1019–25, 2018
  68. Gonzalez AE, Codd EE, Horton J, et al. Oxfendazole: a promising agent for the treatment and control of helminth infections in humans. Expert Rev Anti Infect Ther. 17(1):51–6, 2019
  69. Devi R, Jain A, Hurkat P,et al. Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis. Pharm Res. 32(10):3137–48, 2015
  70. World Health Organization. Epidemicity of Taemia Solium, 2016 ( [Accessed 23 September 2020[